Rua das Taipas, 135, 4050-600 Porto, Portugal NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Instituto de Saúde Pública da Universidade do Porto

E-mail: carina.rodrigues@ispup.up.pt 26 27 Phone: (+351) 222061820 28 **Disclosure statement** 29 30 The authors report no conflict of interest. 31 32 **Funding** This study was funded by national funding from the Foundation for Science 33 and Technology - FCT (Portuguese Ministry of Science, Technology and Higher 34 35 Education), the Operational Programmes Competitiveness and Internationalization (COMPETE 2020) and Human Capital (POCH), Portugal 2020, under the Unidade de 36 Investigação em Epidemiologia - Instituto de Saúde Pública da Universidade do Porto 37 38 (EPIUnit) (POCI-01-0145-FEDER-006862; UID/DTP/04750/2019) and the PhD grant SFRH/BD/111794/2015 (CR). 39 40 Word count abstract: 293 41 42 Word count main text: 2852 43 **Short title** 44 45 COVID-19: impact on pregnancy and breastfeeding

A. Why was this study conducted? 47 48 Pregnant women and newborns are exposed to COVID-19 and at risk for adverse outcomes. The review of evidence is essential to guide preventive action and therapy. 49 B. What are the key findings? 50 Fetal distress and preterm delivery seem to be more frequent among COVID-19 pregnant 51 52 women. Also, evidence on vertical transmission is emerging but the clinical relevance of 53 the fetal infection remains unclear. No evidence links the SARS-CoV-2 virus to 54 transmission via breast milk. C. What does this study add to what is already known? 55 56 The comprehensive review of 212 pregnant women with COVID-19, summarizes the evidence on vertical transmission, as well as adverse maternal and neonatal outcomes. 57 Additionally, it adds the characteristics of the first eight cases of COVID-19 positive 58 59 women delivered in Portugal.

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

CoV-2.

Abstract **Background:** The COVID-19 pandemic is an emerging concern regarding the potential adverse effects during pregnancy. This study reviews knowledge on the impact of COVID-19 on pregnancy and describes the outcome of published cases of pregnant women diagnosed with COVID-19, as well as the characteristics of COVID-19 positive women who delivered in Portugal by 31 of March 2020. Methods: Searches were conducted in PubMed® up to 8 April 2020, using PRISMA standards, to identify original published studies describing pregnant women at any gestational age diagnosed COVID-19. There were no date or language restrictions on the search. All identified studies were included irrespective of assumptions on study quality. Portuguese cases were ascertained by contact with all Portuguese maternities and based on the information provided by their health professionals. **Results:** We identified 30 original studies reporting 212 cases of pregnant women with COVID-19 (30 discharged while pregnant), 200 from China and 12 from other countries. The 182 published deliveries resulted in one stillbirth and 185 live births. Four women with severe COVID-19 required admission to an intensive care unit but no cases of maternal death were reported. There was one neonatal death. Preterm births occurred in 28.7% of cases, but it is unclear whether this was iatrogenic. All cases with amniotic fluid, placenta, and/or cord blood analyzed for the SARS-CoV-2 virus were negative. Four newborns were positive for SARS-CoV-2 and three newborns had high levels of IgM antibodies. None of the first eight infants born in Portugal tested positive. Breast milk

samples from 13 mothers and described in seven studies showed no evidence of SARS-

Conclusion: The evidence related to the effect of COVID-19 on pregnant women is still limited. Pregnant women and newborns should be considered particularly vulnerable populations regarding COVID-19 prevention and management strategies.

Keywords:

89 COVID-19, SARS-COV-2, Pregnancy, Vertical transmission, Breastfeeding, Perinatal

90 outcomes, systematic review.

Introduction

91

113

114

115

92 The disease resulting from infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and designated COVID-19 by the World Health 93 Organization (WHO) was first identified in humans in December 2019, in the city of 94 Wuhan, China, and can present from asymptomatic to a severe acute respiratory infection 95 requiring intensive care.^{2, 3} The infection can occur at any age, but COVID-19 is 96 proportionally uncommon in children (<1% of the total cases). The infection fatality rate 97 is around 1% but much higher in older people or those with pre-existing medical 98 conditions (such as heart disease, diabetes, COPD).^{2,4} 99 100 Person-to-person transmission of COVID-19 is well established and can occur when an 101 infected person coughs, sneezes or speaks and scattered droplets are inhaled or reach the 102 mucous membranes of the mouth, nose or eyes of susceptible. COVID-19 can also be 103 transmitted through direct hand contact with surfaces or objects contaminated with SARS-CoV-2 followed by contact with the mouth, nose or eyes.² 104 105 Pregnant women and newborns receive special attention and there is an emerging concern with the potential risk of SARS-COV-2 vertical transmission (from mother to fetus) or 106 107 associated malformations, and contagion during delivery and breastfeeding; likewise, it is important to determine the potential adverse effects of COVID-19 in pregnant women.⁵-108 ⁸ However, in general, the available information remains scarce. 109 This study reviews published cases of pregnant women diagnosed with COVID-19 and 110 presents the characteristics of the first cases of COVID-19 positive women who delivered 111 in Portugal as identified by the 31st of March 2020. 112

Methods

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

The review follows the Preferred Reporting of Systematic Reviews and Meta-Analysis (PRISMA) guidelines.^{9, 10} We searched PubMed® up to 8 April 2020 to identify original published studies describing pregnant women at any gestational age diagnosed with COVID-19 (confirmed by clinical/radiological evidence of pneumonia compatible with SARS-CoV-2 and/or by quantitative real-time polymerase chain reaction (PCR) or dual fluorescence PCR of SARS-CoV-2 infection). The following search expression was used [(COVID-19 OR 2019-nCoV OR "novel coronavirus" OR SARS-CoV-2 OR "coronavirus 2") AND (pregnancy OR delivery OR pregnant OR obstetric* OR maternal OR perinatal OR breastfeeding)]. Also, reference tracking was carried out to identify other potential studies to be included. Each reference retrieved was screened independently by two researchers (IB and RD) following predefined criteria to determine eligibility for the systematic review. Studies were excluded if: (1) did not involve humans (e.g. in vitro or animal research); (2) nonoriginal articles (e.g. book chapters, review articles, editorials, comments, guidelines); (3) data not reporting pregnant women diagnosed with COVID-19; and (4) duplicate studies or evaluating the same sample. There were no date or language restrictions on the search. Two researchers (IB and RD) reviewed the included studies and extracted the following data: collection period, maternal age, pregnancy complications, type of delivery, indication for cesarean section, gestational age at birth (or at admission), pregnancy outcome, maternal admission to intensive care unit, maternal death, neonatal outcomes (birth weight, Apgar at 1 and 5 minutes, neonatal complications, breastfeeding),

intrauterine and/or neonatal samples collected for detection of SARS-CoV-2 (such as

141

142

143

144

145

146

147

148

149

150

151

152

153

154

159

160

161

162

163

164

165

166

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

women were in the third trimester of pregnancy and there was only one study reporting pregnant women in the first trimester.¹⁷ Table 2 describes the characteristics of the first eight cases of COVID-19 positive women delivered in Portugal, until the 31st of March 2020. Vertical transmission of COVID-19 All cases in which amniotic fluid, placenta, and/or cord blood were analyzed for SARS-CoV-2 virus were negative. 5, 11, 13, 15, 18-26 Most studies detected the SARS-CoV-2 RNA by real-time reverse transcriptionpolymerase chain reaction (RT-PCR) using samples from the newborn's nasopharyngeal or throat, sample collection varying from immediately to 9 days after birth. Two studies also used maternal and neonatal sera samples to test for IgG and IgM antibodies. 27, 28 Four newborns (2.2%) presented positive oral swabs for SARS-CoV-2.21, 24, 25, 29 In a cohort of 33 newborns from mothers with COVID-19, admitted to the Pediatric Hospital of Wuhan, three of the newborns had positive RT-PCR for SARS-CoV-2 in nasopharyngeal and anal swabs collected on the second and fourth days after delivery. with negative results on the sixth day for two newborns and on the seventh day for another. However, placenta, amniotic fluid, and cord blood samples were not analyzed.²⁹ There is yet another case of a newborn with a positive RT-PCR for SARS COV-2 in one throat swab collected at 36 hours after birth. 21, 24 However, it was not possible to confirm whether it was a real case of intrauterine transmission since the umbilical cord and placenta blood samples were negative for SARS-CoV-2 and the possibility of postnatal contact could not be discarded. 21, 24 No other study reported positive results for the SARS-

CoV-2 virus in nasopharyngeal exudates from newborns of mothers diagnosed with

Maternal and neonatal outcomes

evidenced SARS-CoV-2 virus. 5, 15, 16, 20-22, 28

The clinical and obstetric conditions most frequently reported were fetal distress (n=20), gestational diabetes (n=13), gestational hypertension (n=11), premature rupture of membranes (PROM) (n=7), anemia (n=5), placenta previa/bleeding in the third trimester (n=5), pre-eclampsia (n=4), hypothyroidism (n=4), chronic hypertension (n=3), thalassemia(n=2), polycystic ovary syndrome (n=2), cholecystitis (n=2), asthma (n=2), diabetes mellitus type 2 (n=2), placental abruption (n=1), oligohydramnios(n=1), polyhydramnios (n=1), hepatitis B infection (n=1) and mitral valve and tricuspid valve replacement (n=1). In one study that compared groups of pregnant women with and without COVID-19, there were no significant differences in the occurrence of gestational diabetes, severe pre-eclampsia, PROM, fetal distress, meconium-stained amniotic fluid, premature delivery, neonatal asphyxia and procedures for severe post-partum bleeding.³⁰

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

11

symptoms. In a New York's hospital that implemented universal SARS-CoV-2 testing in

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

all pregnant women admitted for delivery, 15.4% of them were positive for SARS-CoV-2, but 87.9% were asymptomatic.³⁸ Although most of the published cases confirm the absence of transmission of the SARS-CoV-2 virus antenatally or intrapartum, at least when the infection occurs in the third trimester of pregnancy, 5, 11, 13, 15, 18-26 emerging evidence has suggested that vertical transmission is possible. 21, 24, 25, 27-29 However, the evidence is still limited to a reduced number of reported cases, large variability in the type of biological material analyzed and the time of its collection. Even if vertical transmission occurred in the reported cases, the proportion would be low, below 5% of the published cases. Regarding the effect of the SARS-CoV-2 virus on the fetus, no congenital malformation has been reported so far and the association of COVID-19 and fetal malformation seems unlikely considering the reduced risk of intrauterine infection.³⁷ Higher risk of fetal distress and preterm births have been reported, but it is unclear if preterm birth occurs spontaneously (spontaneous onset of labor or following PROM) or is iatrogenic. The evidence related to the effect of COVID-19 on pregnant women is still limited. The clinical characteristics of COVID-19 were similar to those described in nonpregnant women, suggesting that the prognosis is not worse in pregnant women, although the number of cases studied is still reduced.^{5, 18, 31-34} A recent systematic review summarized the clinical manifestations of 108 pregnant women confirmed with COVID-19 and most of them presented fever (68%) and coughing (34%), and lymphocytopenia (59%) with elevated C-reactive protein (70%).³⁹ The maternal and neonatal outcomes observed so far are quite different from the two most serious coronavirus-related previous epidemics.^{7, 40-53} The first also appeared in China, in 2002-03, and was characterized by severe respiratory infections caused by the Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV). The second occurred in 2012,

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

initially in the Middle East, the Middle East Respiratory Syndrome - Coronavirus (MERS-CoV). 7,40 These epidemics have demonstrated the ability of coronavirus to cause serious complications during pregnancy, 43,53 with worse prognosis in pregnant women than non-pregnant women. 42, 54 In the 2002 epidemic, 12 pregnant women were infected with SARS-CoV, with a fatality rate of 25%. ⁵³ Among the seven pregnant women infected in the first trimester, four had a miscarriage.⁵³ Two of the five pregnant women infected during the second or third trimester had fetal growth restriction and four had a preterm delivery (one spontaneous; three induced by the maternal condition).⁵³ In a review of the pregnancy outcomes of 11 women infected with MERS-CoV, seven pregnant women required admission to the intensive care unit and three died, of which only one had one comorbidity (asthma). Two fetal deaths occurred, and three of nine newborns were preterm.⁴³ However, considering that SARS-CoV-2 has genetic homology and some clinical similarities to SARS-CoV and MERS-CoV, and the immunological and physiological changes that occur during pregnancy, such as in cell-mediated immunity or lung function, that affect both the susceptibility and the clinical severity of pneumonia, it is important to pay particular attention to the monitoring of pregnant women with COVID-19, because maternal and perinatal adverse outcomes are potentially relevant.^{7,40} Although there were no maternal deaths described, possible maternal deaths were reported in social media, but without any robust evidence.³⁷ Furthermore, one study reported two asymptomatic pregnant women at admission for delivery that rapidly evolved to severe COVID-19 disease requiring admission to an intensive care unit. 12 Thus, it is essential to prevent the infection of COVID-19 and any other viral respiratory infection, as these infections represent an increased risk for the pregnant woman and for

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

the pregnancy itself. ^{7, 55, 56} It is therefore extremely important that pregnant women adopt preventive actions for COVID-19 with great intensity.³⁷ For pregnant women with suspected or confirmed infection with SARS-CoV-2, recommendations for health professionals and services have already been published. 37, 55, ⁵⁷⁻⁵⁹ In Portugal, we can estimate that about 80,000 pregnant women are exposed to the pandemic at different gestational ages, which represents an important challenge for individual and public health, to avoid infection in this population that should be considered at higher risk. Most women in this review had a cesarean section, many of them without a clear medical indication. The decision on the type of delivery in pregnant women with suspected or confirmed infection with COVID-19 should take into account the maternal and fetal clinical characteristics, as in normal practice, and not the diagnosis of COVID-19 infection per se. Thus, there is no obstetric contraindication to any mode of delivery, unless the pregnant woman's clinical condition implies an emergent decision.³⁷ The limited scientific knowledge currently available makes it difficult to develop specific breastfeeding recommendations. There is not enough scientific evidence to unequivocally state that there is no possibility that mothers with COVID-19 can transmit the virus through breast milk. 55 Therefore, recommendations should be based on the available data ^{5, 15, 16, 20-22, 28} and the analogy with past circumstances and predictable costs and benefits. Breastfeeding is recognized as the best form of child feeding due to the countless benefits for both the mother and the newborn, including the protection against gastrointestinal and respiratory infections.⁶⁰ Thus, considering the benefits of breastfeeding and the fact that the transmission of other respiratory viruses is insignificant through breast milk, there is no indication to stop breastfeeding. According to the recommendations of WHO/UNICEF⁶¹ and the Center for Disease Control and Prevention (CDC) of the United

Conclusion

case. 30, 33, 34, 36

According to this review, fetal distress and preterm delivery seem to be more frequent among pregnant women with COVID-19. There is emerging evidence on possible vertical transmission (four positive results in the neonatal oral swabs for SARS-CoV-2 were reported and three newborns had high values of IgM antibodies), but the clinical relevance of the fetal infection is unclear. None of the first eight infants born in Portugal tested positive for the SARS-CoV-2. So far, there is no evidence that the SARS-CoV-2 virus is transmitted through breast milk. Maternal deaths were not reported and hospitalizations in intensive care were uncommon. Although the complications appear to be similar to those of non-pregnant women, services must be prepared to attend to complications,

especially in pregnant women with comorbidities. Therefore, pregnant women and newborns should be considered particularly vulnerable populations regarding COVID-19 prevention and management strategies. Information, counseling and adequate monitoring are essential to prevent major adverse effects of SARS-CoV-2 infection during pregnancy.

Acknowledgment

The authors are grateful to the health professionals who provided and confirmed the cases of pregnant women diagnosed with COVID-19 in Portugal: Alcides Pereira, Alexandra Almeida, Alexandrina Portela, Almerinda Pereira, Anselmo Costa, Gabriela Mimosa, Pedro Vieira da Silva, Rosalina Barroso, Teresa Rodrigues, Teresa Tomé.

Authors' contributions

Carina Rodrigues and Henrique Barros: Conceptualization, Original draft preparation. Inês Baía and Rosa Domingues: Methodology, Data curation, Writing-Reviewing, and Editing. All authors read and approved the final manuscript.

References

- 372 HUI DS, E IA, MADANI TA, et al. The continuing 2019-nCoV epidemic threat of 373 1. 374 novel coronaviruses to global health - The latest 2019 novel coronavirus 375 outbreak in Wuhan, China. Int J Infect Dis 2020;91:264-66. CALDAS JP, TAVARES M. Epidemiologia da COVID-19. 2020. [Internet]. [cited 376 2. 2020 Apr 13] Available from: 377 http://asset.youoncdn.com/ab296ab30c207ac641882479782c6c34/070b44658f5 378 379 569888804a14826ae273c.pdf CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 380 3. 381 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive 382 study. Lancet 2020;395:507-13. RUSSELL TW, HELLEWELL J, JARVIS CI, et al. Estimating the infection and case 383 4. fatality ratio for COVID-19 using age-adjusted data from the outbreak on the 384 Diamond Princess cruise ship. medRxiv 2020:2020.03.05.20031773. 385 5. CHEN H, GUO J, WANG C, et al. Clinical characteristics and intrauterine vertical 386 387 transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet 2020. 388 389 QIAO J. What are the risks of COVID-19 infection in pregnant women? The 6. 390 Lancet. RASMUSSEN SA, SMULIAN JC, LEDNICKY JA, WEN TS, JAMIESON DJ. 7. 391 Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need 392
- 393 to know. Am J Obstet Gynecol 2020.
- FAVRE G, POMAR L, MUSSO D, BAUD D. 2019-nCoV epidemic: what about 394 8. pregnancies? Lancet 2020;395:e40. 395

9. LIBERATI A, ALTMAN DG, TETZLAFF J, et al. The PRISMA statement for 396 397 reporting systematic reviews and meta-analyses of studies that evaluate health 398 care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100. 10. MOHER D, SHAMSEER L, CLARKE M, et al. Preferred reporting items for 399 400 systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. 401 402 11. IQBAL SN, OVERCASH R, MOKHTARI N, et al. An Uncomplicated Delivery in a Patient with Covid-19 in the United States. N Engl J Med 2020. 403 404 12. Breslin N, Baptiste C, Miller R, et al. COVID-19 in pregnancy: early 405 lessons. Am J Obstet Gynecol 2020:100111. 13. 406 LEE DH, LEE J, KIM E, WOO K, PARK HY, AN J. Emergency cesarean section on 407 severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) confirmed 408 patient. Korean J Anesthesiol 2020. ZAMBRANO LI, FUENTES-BARAHONA IC, BEJARANO-TORRES DA, et al. A 409 14. pregnant woman with COVID-19 in Central America. Travel Med Infect Dis 410 2020:101639. 411 412 15. KALAFAT E, YAPRAK E, CINAR G, et al. Lung ultrasound and computed 413 tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet Gynecol 2020. 414 GIDLÖF S, SAVCHENKO J, BRUNE T, JOSEFSSON H. COVID-19 in pregnancy with 415 16. comorbidities: More liberal testing strategy is needed. Acta Obstet Gynecol 416 Scand 2020. 417 418 17. LIU D, LI L, WU X, et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. AJR 419

Am J Roentgenol 2020:1-6.

- 421 18. ZHU H, WANG L, FANG C, et al. Clinical analysis of 10 neonates born to mothers
- with 2019-nCoV pneumonia. Transl Pediatr 2020;9:51-60.
- 423 19. WANG X, ZHOU Z, ZHANG J, ZHU F, TANG Y, SHEN X. A case of 2019 Novel
- 424 Coronavirus in a pregnant woman with preterm delivery. Clin Infect Dis 2020.
- 425 20. LIY, ZHAOR, ZHENGS, et al. Lack of Vertical Transmission of Severe Acute
- 426 Respiratory Syndrome Coronavirus 2, China. Emerg Infect Dis 2020;26.
- 427 21. WANG S, GUO L, CHEN L, et al. A case report of neonatal COVID-19 infection in
- 428 China. Clin Infect Dis 2020.
- 429 22. FAN C, LEI D, FANG C, et al. Perinatal Transmission of COVID-19 Associated
- 430 SARS-CoV-2: Should We Worry? Clin Infect Dis 2020.
- 431 23. LIAO X, YANG H, KONG J, YANG H. Chest CT Findings in a Pregnant Patient
- with 2019 Novel Coronavirus Disease. Balkan Med J 2020.
- 433 24. YUN, LIW, KANG Q, et al. Clinical features and obstetric and neonatal
- outcomes of pregnant patients with COVID-19 in Wuhan, China: a
- retrospective, single-centre, descriptive study. Lancet Infect Dis 2020.
- 436 25. LIU W, WANG Q, ZHANG Q, et al. Coronavirus Disease 2019 (COVID-19)
- During Pregnancy: A Case Series. Preprints 2020.
- 438 26. CHEN S, HUANG B, LUO DJ, et al. [Pregnant women with new coronavirus
- infection: a clinical characteristics and placental pathological analysis of three
- cases]. Zhonghua Bing Li Xue Za Zhi 2020;49:E005.
- 27. ZENG H, Xu C, FAN J, et al. Antibodies in Infants Born to Mothers With
- 442 COVID-19 Pneumonia. Jama 2020.
- 443 28. DONG L, TIAN J, HE S, et al. Possible Vertical Transmission of SARS-CoV-2
- From an Infected Mother to Her Newborn. Jama 2020.

- 29. ZENG L, XIA S, YUAN W, et al. Neonatal Early-Onset Infection With SARS-
- 446 CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China.
- JAMA Pediatr 2020.
- 448 30. ZHANG L, JIANG Y, WEI M, et al. [Analysis of the pregnancy outcomes in
- pregnant women with COVID-19 in Hubei Province]. Zhonghua Fu Chan Ke Za
- 450 Zhi 2020;55:E009.
- 451 31. LIU Y, CHEN H, TANG K, GUO Y. Clinical manifestations and outcome of SARS-
- 452 CoV-2 infection during pregnancy. J Infect 2020.
- 453 32. Chen S, Liao E, Shao Y. Clinical analysis of pregnant women with 2019 novel
- 454 coronavirus pneumonia. J Med Virol 2020.
- 455 33. CHEN R, ZHANG Y, HUANG L, CHENG BH, XIA ZY, MENG QT. Safety and
- efficacy of different anesthetic regimens for parturients with COVID-19
- undergoing Cesarean delivery: a case series of 17 patients. Can J Anaesth 2020.
- 458 34. LIU H, LIU F, LI J, ZHANG T, WANG D, LAN W. Clinical and CT imaging features
- of the COVID-19 pneumonia: Focus on pregnant women and children. J Infect
- 460 2020.
- 461 35. XIA H, ZHAO S, WU Z, LUO H, ZHOU C, CHEN X. Emergency Caesarean delivery
- in a patient with confirmed coronavirus disease 2019 under spinal anaesthesia.
- 463 Br J Anaesth 2020.
- 464 36. LI N, HAN L, PENG M, et al. Maternal and neonatal outcomes of pregnant women
- with COVID-19 pneumonia: a case-control study. medRxiv
- 466 2020:2020.03.10.20033605.
- 467 37. ROYAL COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS,
- 468 ROYAL COLLEGE OF MIDWIVES, ROYAL COLLEGE OF PAEDIATRICS
- 469 AND CHILD HEALTH, PUBLIC HEALTH ENGLAND AND HEALTH

PROTECTION SCOTLAND (2020). Coronavirus (COVID-19) Infection in 470 471 Pregnancy: Information for healthcare professionals (Version 8). [Internet]. 472 [cited 2020 Apr 9] Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/2020-04-17-473 474 coronavirus-covid-19-infection-in-pregnancy.pdf 475 38. SUTTON D, FUCHS K, D'ALTON M, GOFFMAN D. Universal Screening for SARS-476 CoV-2 in Women Admitted for Delivery. N Engl J Med 2020. 477 39. ZAIGHAM M, ANDERSSON O. Maternal and Perinatal Outcomes with COVID-19: 478 a systematic review of 108 pregnancies. Acta Obstet Gynecol Scand 2020. 479 40. SCHWARTZ DA, GRAHAM AL. Potential Maternal and Infant Outcomes from 480 (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses 2020;12. 481 482 41. STOCKMAN LJ, LOWTHER SA, COY K, SAW J, PARASHAR UD. SARS during pregnancy, United States. Emerg Infect Dis 2004;10:1689-90. 483 42. MAXWELL C, McGEER A, TAI KFY, SERMER M. No. 225-Management 484 Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected 485 486 or Probable Severe Acute Respiratory Syndrome (SARS). J Obstet Gynaecol 487 Can 2017;39:e130-e37. 43. ALFARAJ SH, AL-TAWFIQ JA, MEMISH ZA. Middle East Respiratory Syndrome 488 Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & 489 review of the literature. J Microbiol Immunol Infect 2019;52:501-03. 490 44. ALSEREHI H, WALI G, ALSHUKAIRI A, ALRADDADI B. Impact of Middle East 491 492 Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infect Dis 2016;16:105.

- 494 45. ASSIRI A, ABEDI GR, AL MASRI M, BIN SAEED A, GERBER SI, WATSON JT.
- 495 Middle East Respiratory Syndrome Coronavirus Infection During Pregnancy: A
- 496 Report of 5 Cases From Saudi Arabia. Clin Infect Dis 2016;63:951-53.
- 497 46. HAINES CJ, CHU YW, CHUNG TK. The effect of Severe Acute Respiratory
- 498 Syndrome on a hospital obstetrics and gynaecology service. Bjog 2003;110:643-
- 499 5.
- 500 47. JEONG SY, SUNG SI, SUNG JH, et al. MERS-CoV Infection in a Pregnant Woman
- in Korea. J Korean Med Sci 2017;32:1717-20.
- 502 48. JIANG X, GAO X, ZHENG H, et al. Specific immunoglobulin g antibody detected
- in umbilical blood and amniotic fluid from a pregnant woman infected by the
- coronavirus associated with severe acute respiratory syndrome. Clin Diagn Lab
- 505 Immunol 2004;11:1182-4.
- 506 49. MALIK A, EL MASRY KM, RAVI M, SAYED F. Middle East Respiratory
- 507 Syndrome Coronavirus during Pregnancy, Abu Dhabi, United Arab Emirates,
- 508 2013. Emerg Infect Dis 2016;22:515-7.
- 509 50. OWOLABIT, KWOLEK S. Managing obstetrical patients during severe acute
- respiratory syndrome outbreak. J Obstet Gynaecol Can 2004;26:35-41.
- 511 51. PAYNE DC, IBLAN I, ALQASRAWI S, et al. Stillbirth during infection with Middle
- East respiratory syndrome coronavirus. J Infect Dis 2014;209:1870-2.
- 513 52. ROBERTSON CA, LOWTHER SA, BIRCH T, et al. SARS and pregnancy: a case
- report. Emerg Infect Dis 2004;10:345-8.
- 515 53. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of
- women with severe acute respiratory syndrome. Am J Obstet Gynecol
- 517 2004;191:292-7.

54. LAM CM, WONG SF, LEUNG TN, et al. A case-controlled study comparing 518 519 clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. Bjog 2004;111:771-4. 520 521 CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). 55. 522 Pregnancy & Breastfeeding: Information about Coronavirus Disease 2019. 523 [Internet]. [cited 2020 Apr 9] Available from: 524 https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-525 breastfeeding.html YANG H, WANG C, POON LC. Novel coronavirus infection and pregnancy. 526 56. 527 Ultrasound Obstet Gynecol 2020. FAVRE G, POMAR L, QI X, NIELSEN-SAINES K, MUSSO D, BAUD D. Guidelines 528 57. for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis 529 530 2020. POON LC, YANG H, LEE JCS, et al. ISUOG Interim Guidance on 2019 novel 531 58. coronavirus infection during pregnancy and puerperium: information for 532 healthcare professionals. Ultrasound Obstet Gynecol 2020. 533 LIANG H, ACHARYA G. Novel corona virus disease (COVID-19) in pregnancy: 534 59. 535 What clinical recommendations to follow? Acta Obstet Gynecol Scand 2020. 60. VICTORA CG, BAHL R, BARROS AJ, et al. Breastfeeding in the 21st century: 536 epidemiology, mechanisms, and lifelong effect. Lancet 2016;387:475-90. 537 UNICEF/WORLD HEALTH ORGANIZATION. Coronavirus disease (COVID-538 61. 19): What parents should know. [Internet]. [cited 2020 Apr 9] Available from: 539 https://www.unicef.org/stories/novel-coronavirus-outbreak-what-parents-should-know 540 541 62. Luo Y, Yin K. Management of pregnant women infected with COVID-19. Lancet Infect Dis 2020. 542

64. WEN R, SUN Y, XING QS. A patient with SARS-CoV-2 infection during pregnancy in Qingdao, China. J Microbiol Immunol Infect 2020.

546

Table 1. Characteristics of pregnant women diagnosed with COVID-19 described in the literature (n=212).

	n/N (%)
faternal characteristics	(
Age, years (min-max)	22-43
Country of hospital admission	
China	200/212 (94.3)
United States of America	8/212 (3.8)
South Korea	1/212 (0.5)
Honduras	1/212 (0.5)
Turkey	1/212 (0.5)
Sweden	1/212 (0.5)
regnancy complications	. (***)
Fetal distress	20/212 (9.4)
Gestational diabetes	13/212 (6.1)
Gestational hypertension	11/212 (5.2)
PROM	7/212 (3.3)
Anemia	5/212 (2.4)
Placenta previa/bleeding	5/212 (2.4)
Preeclampsia	4/212 (1.9)
Hypothyroidism	4/212 (1.9)
Chronic hypertension	3/212 (1.4)
Thalassemia	2/212 (0.9)
Polycystic ovary syndrome	2/212 (0.9)
Cholecystitis	2/212 (0.9)
Asthma	2/212 (0.9)
Diabetes mellitus type 2	2/212 (0.9)
Placental abruption	1/212 (0.5)
Oligohydramnios	1/212 (0.5)
Polyhydramnios	1/212 (0.5)
Hepatitis B infection	1/212 (0.5)
Mitral valve and tricuspid valve replacement	1/212 (0.5)
regnancy characteristics/outcomes	
Pregnant women at discharge (undelivered)	30/212 (14.2)
Multiple pregnancies	4/212 (1.9)
Deliveries	182/212 (85.8)
Multiple pregnancies delivered	4/182 (2.2)
Stillbirths	1/186 (0.5)

	Live births	185/186 (99.5)				
	Cesarean section	139/158 (88.0)				
	Preterm birth (<37 weeks of gestation)	45/157 (28.7)				
N	faternal outcomes					
	Maternal deaths	0/212 (0.0)				
	Maternal admission to Intensive Care Unit	4/212 (1.9)				
Neonatal outcomes						
	Neonatal deaths	1/185 (0.5)				
	SARS-CoV-2 infection confirmed by oral swabs	4/185 (2.2)				
	High levels of SARS-CoV-2 IgM antibodies	3/185 (1.6)				
Type of intrauterine/ neonatal samples collected and results						
	Placenta	21/186 (11.3)				
	Positive results	0/21 (0.0)				
	Cord blood	13/186 (7.0)				
	Positive results	0/13 (0.0)				
	Amniotic fluid	14/186 (7.5)				
	Positive results	0/14 (0.0)				
	Newborn's oral swabs	70/185 (33.8)				
	Positive results	4/70 (5.7)				
	Measurement of SARS-CoV-2 IgM and IgG antibody	7/185 (3.8)				
	Reactive IgM	3/7 (42.8)				
	Reactive IgG	6/7 (85.7)				
	Breast milk	13/185 (7.0)				
	Positive results	0/13 (0.0)				

Table 2. Characteristics of COVID-19 positive women delivered in Portugal, until the 31st of March 2020.

Case	Local	Sex	Gestation al age	Type of delivery	Birth weight	SARS-CoV-2 confirmed on
					(grams)	the infant
1	Porto	Female	38	Instrumental vaginal (vacuum)	3240	Negative
2	Porto	Male	40	Cesarean	3110	Negative
3	Lisboa	Male	30	Cesarean	1530	Negative
4	Porto	Male	40	Vaginal	4050	Negative
5	Braga	Male	36	Cesarean	2940	Negative
6	Matosinhos	Female	39	Cesarean	2480	Negative
7	Lisboa	Female	40	Cesarean	3005	Negative
8	Amadora	Male	39	Cesarean	3300	Negative